A Preview Of Cara Therapeutics's Earnings
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) is scheduled to release its quarterly earnings report on 2024-03-04, with analysts expecting an EPS of $-0.41. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's EPS miss leading to a 7.2% drop in share price. Over the last year, CARA shares have declined by 91.22%, indicating a challenging period for long-term shareholders. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.
March 01, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cara Therapeutics is expected to report an EPS of $-0.41 for the quarter. Past earnings have shown a significant impact on stock prices, with a notable 91.22% decline over the last year.
Given the expected EPS of $-0.41 and the historical sensitivity of CARA's stock price to earnings reports and guidance, there's a potential for negative short-term impact. The stock has already been on a downward trend, losing 91.22% over the last year, indicating investor skepticism. The company's guidance will be crucial; however, the recent history of stock price reactions suggests a cautious outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100